Harrow in the Pivotal Point Check: Ophthalmology on the Rise – Q4 Revenues Nearly Doubled and Strong Forecast for 2025!
Reading Time: 2 minutes
Harrow specializes in innovative ophthalmological therapies in ophthalmology. In the fourth quarter, revenue nearly doubled compared to the previous year. The company benefits from the aging population and increasing demand for chronic eye therapies. The stock price of Harrow rose by over 15% on March 18, 2025. The trigger was the encouraging preliminary financial results for the 4th quarter and the entire year of 2024, as well as the revenue forecast for 2025. Harrow specializes in ophthalmology. The company focuses on the discovery,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
